Synchron has paused clinical trials for its second-generation brain implant, the Stentrode, after it did not perform as expected in initial tests. The company plans to upgrade the device's hardware and has temporarily halted participant enrollment while addressing the identified performance issue with the lead that connects the implant to its electronics.